These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38950402)

  • 21. User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
    Takaori K; Iwatani H; Yamato M; Ito T
    BMC Nephrol; 2021 Jan; 22(1):7. PubMed ID: 33407242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
    JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.
    Chen PM; Lai TS; Chen PY; Lai CF; Wu V; Chiang WC; Chen YM; Wu KD; Tsai TJ
    J Formos Med Assoc; 2014 Apr; 113(4):219-26. PubMed ID: 24512756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive agents for preventing diabetic kidney disease.
    Lv J; Perkovic V; Foote CV; Craig ME; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD004136. PubMed ID: 23235603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
    Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
    Yang Y; Ma YP; Zhang Z; Dai PL; Li P; Li WG
    Clin Nephrol; 2018 Jun; 89(6):445-454. PubMed ID: 29208203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
    Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
    J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dual vs single renin-angiotensin-aldosterone system blockade in chronic kidney disease: An updated meta-analysis of randomized controlled trials.
    Zhao M; Qu H; Wang R; Yu Y; Chang M; Ma S; Zhang H; Wang Y; Zhang Y
    Medicine (Baltimore); 2021 Sep; 100(35):e26544. PubMed ID: 34477114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
    Gayat E; Hollinger A; Cariou A; Deye N; Vieillard-Baron A; Jaber S; Chousterman BG; Lu Q; Laterre PF; Monnet X; Darmon M; Leone M; Guidet B; Sonneville R; Lefrant JY; Fournier MC; Resche-Rigon M; Mebazaa A; Legrand M;
    Intensive Care Med; 2018 May; 44(5):598-605. PubMed ID: 29766216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Qiao Y; Shin JI; Sang Y; Inker LA; Secora A; Luo S; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    Mayo Clin Proc; 2019 Nov; 94(11):2220-2229. PubMed ID: 31619367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.
    Chu CD; Powe NR; Estrella MM; Shlipak MG; McCoy IE; Tuot DS
    Mayo Clin Proc; 2022 Nov; 97(11):2099-2106. PubMed ID: 36210196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.